REG - IP Group PLC - Secondary sale of minority holdings in portfolio

IPAnnouncement

09/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241209:nRSI3025Pa&default-theme=true

RNS Number : 3025P  IP Group PLC  09 December 2024

 FOR RELEASE ON  9 December 2024

 

 

Secondary sale of minority holdings in portfolio companies

-     Includes nine companies across balance sheet & managed funds

-     Balance sheet proceeds of up to c.£15m at small overall premium to
carrying value

-     Intention for all proceeds to be used to increase ongoing share
buyback programme

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in
breakthrough science and innovation companies with the potential to create a
better future for all, is pleased to announce that it has agreed the sale of
minority holdings in nine portfolio companies across its balance sheet and
managed funds to a new fund managed by Lexham Partners.

The Group expects to generate up to approximately £15m of cash proceeds from
the 6 balance sheet holdings included in the transaction. These sales are
expected to be at a small overall premium to the HY24 balance sheet value. On
completion of the sales, some of which are subject to customary private
company transfer conditions, all proceeds received are intended to be used to
further increase the Group's current share buyback programme. If these sales
complete as planned, this will increase the buyback programme by a further
£15m to a total of £45m.

IP Group remains a committed and supportive shareholder to the portfolio
companies included in this sale and the shares sold represent, on average,
less than 10% of the Group's holding in each company.

Greg Smith, Chief Executive of IP Group, said: "This transaction creates new
relationships with a group of long-term investors and further validates the
quality of the Group's portfolio and our valuation approach. IP Group has
performed strongly in generating cash from exits this year at or above
carrying values and we remain compelled by our portfolio and the opportunity
to deliver impact and returns for shareholders. The Board believes the current
share price significantly undervalues the Group's portfolio and has decided it
will allocate all cash proceeds received from this secondary sale to our
ongoing buyback."

Dominic Perks, Managing Partner of Lexham Partners, said: "Lexham is delighted
to become shareholders alongside IP Group in some of the most exciting British
innovation companies. We look forward to deepening our partnership with IP
Group and supporting the portfolio companies to fulfil their growth
potential."

In the year to date, IP Group has received £57m of cash proceeds from exits,
compared with £38.6m received in 2023. Since the current share buyback
programme was announced in December 2023, the Group has bought back 60.5m
shares, approximately 6% of the opening shares in issue, for a total of
£26.7m. Since 2021, the Group has delivered more than £100m of cash returns
to shareholders via dividends and share buybacks.

The Group anticipates receiving an additional £134m of cash, of which £15m
is subject to deferral, for its holding in Featurespace once that transaction
completes. In addition, the Group anticipates receiving additional cash
proceeds after Intelligent Ultrasound Group plc affirmed its intention to make
a 'material return of capital to shareholders'.

As of 30 November 2024, IP Group had £176m gross cash and deposits, and the
Group's holdings in listed companies were £167m, which together represented
approximately 80% of the Group's market capitalisation at that date.

 

 

 

For more information, please contact:

 

 IP Group plc                       www.ipgroupplc.com
 Liz Vaughan-Adams, Communications  +44 (0) 20 7444 0062/+44 (0) 7967 312125
 Portland
 Alex Donaldson                     +44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most
active UK based, early-stage science investor, we develop and support some of
the world's most exciting businesses in deeptech, life sciences and cleantech
(under our Kiko Ventures brand). Including through funds managed by Parkwalk,
the UK's largest growth EIS fund manager, we back world-changing innovation
emerging from leading universities and research institutions. Our specialist
investment team combines sector expertise with an international approach.
Together we have a strong track record of success, having backed high-profile
companies including Oxford Nanopore Technologies plc, Featurespace, Hinge
Health, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main
Market of the London Stock Exchange under the code IPO. For more information,
please visit our website at www.ipgroupplc.com (http://www.ipgroupplc.com/) .

 

About Lexham Partners

 

Lexham Partners is an investment firm focussed on growth and innovation. The
firm was founded in 2023 by Dominic Perks, former co-founder of Hambro Perks.
Lexham Partners has built a diverse team of investment professionals with deep
industry expertise in Fintech, Healthtech, Life Sciences, Deeptech and
Cleantech. Lexham Partners has received backing from a global network of
investors and is able to support its portfolio companies both with plans to
internationalise and strategic partnerships with a particular capability in
the Middle East.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCTPBBTMTJMTII